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Abstract
Background: Wnt signaling plays an important role in development and maintenance of many organs and tissues.
The most-studied secreted Wnt inhibitors are sclerostin (SOST), Dickkopf-related protein 1 (DKK-1), and secreted
frizzled related protein 1 (SFRP-1) which play important roles in bone turnover. The present study investigated the
relationship between serum Wnt inhibitors and diseases with excessive ossification structures, such as ossification
of posterior longitudinal ligament (OPLL), ankylosing spondylitis (AS), diffuse idiopathic skeletal hyperostosis (DISH),
and ossification of yellow ligament (OYL).
Methods: Twenty-five patients with AS, DISH, OPLL, or OYL were recruited in this study. Fasting peripheral blood
samples were collected from all patients and nine controls. Various biomarkers of bone turnover including osteocalcin
(OSC), osteoprotegerin (OPG), SFRP-1, DKK-1, and SOST were investigated.
Results: Our data showed that serum levels of OSC were higher, but Dkk-1 levels were lower in AS, DISH, OPLL, and
OYL patients than those in the controls. Serum levels of SFRP-1 were significantly higher in DISH patients than those in
the controls. Serum levels of SOST were significantly higher in DISH and OPLL patients than both levels in the controls.
Serum levels of OPG were lower in AS patients than those in the controls. Serum levels of OSC were higher in the
OPLL patients than those in the AS patients. Serum levels of DKK-1, SFRP-1, SOST, and OPG were not significantly
different between the different disease groups.
Conclusions: In this exploratory study, both OSC and DKK-1 levels are correlated with the clinical conditions associated
with excessive ossification, indicating that blood OSC and DKK-1 levels may serve as diagnostic biomarkers for AS, DISH,
OPLL, and OYL. These findings may also help discover potential drug therapies for management of these diseases in
the future.
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Background
Spondyloarthropathies are inflammatory disorders in-
volving peripheral joints, sacroiliac joints, diffuse spine
involvement, and some extra-articular features [1–3].
Ankylosing spondylitis (AS) presents with common and
severe spine involvement. Earlier reports suggested that
AS patients have low trabecular bone mineral density
(BMD) in the spine [4]. Patients with AS are at high risk
of osteoporosis and vertebral fractures [5]. Diffuse idio-
pathic skeletal hyperostosis (DISH) is also an ossifying
diathesis of unknown etiology, characterized by flowing
calcification and ossification on the anterolateral aspect
of contiguous vertebral bodies with no involvement of
apophyseal joints and sacroiliac joints [6]. Ossifying pos-
terior longitudinal ligament (OPLL) is a condition of
abnormal calcification of the posterior longitudinal liga-
ment. The etiology of OPLL has not been fully clarified
[7]. OPLL seems to occur and develop as a result of sys-
temic and local factors in combination with a genetic
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abnormality [8, 9]. Ossification of the yellow ligament
(OYL) is characterized by progressive ectopic bone forma-
tion in the spinal ligaments. Even though the pathogenesis
of OYL is unclear, mechanical stress on the yellow liga-
ment has been identified as a main contributor [10]. The
OPLL and OYL of spine have an unknown etiology and
are troublesome diseases in surgical treatment. Combina-
tions of varying degrees of spondylosis and/or OPLL, and
OYL contribute to thoracic and lumbar neural compres-
sion in North Americans [11].
Excessive ossification of the tissue around the spine,
albeit in different regions, is a common characteristic of
these aforementioned spondyloarthropathies. The exces-
sive ossification causes two serious pathologic problems:
loss of motion occurs between spine segment(s), and the
space-occupying-lesion compresses the neurological
structure. These pathologies always have multiple foci
that are distributed along the spine. OPLL has been re-
ported to be associated with DISH [12, 13], AS [14], and
other spondyloarthropathies [15]. Clinically, DISH and
OPLL, DISH and OYL, OPLL and OYL, and AS and
OYL have indeed been reported to coexist in the same
patients. Because of this overlap, we sought to investi-
gate whether the pathophysiology of these lesions are
similar but show various degrees of activity, or have to-
tally different mechanisms. It might be possible to devise
methods for reversing the progression of these diseases
and preventing the poor prognosis at the late stage once
the mechanisms of the excessive ossification in these
diseases are clarified.
Few reports describe the relationships between AS,
DISH, OPPL, OYL, and the Wnt pathway. Wnt signaling
plays an important role in development and mainten-
ance of many organs and tissues [16]. Although Wnt sig-
nals through several pathways to regulate cell growth,
differentiation, function, and death, the Wnt/β-catenin
or canonical pathway appears to be particularly import-
ant for bone biology [17, 18]. The Wnt/β-catenin path-
way is an osteogenic pathway. The most-studied
secreted Wnt inhibitors are sclerostin (SOST), dickkopfs
(DKKs), and secreted frizzled related proteins (SFRPs),
which likely play important roles in bone turnover [19].
SOST, a secreted glycoprotein of osteocytes, is thought
to directly bind to lipoprotein receptor-related proteins
(LRPs) and prevent Wnt ligand binding [20]. SFRP-1 is
thought to competitively inhibit binding of Wnts to the
LRP/Frzled complex by acting as decoy receptors [21].
Similar to SOST, DKK-1 is a secreted antagonist of
Wnt/β-catenin signaling which also functions by binding
to the LRP5/6 co-receptor. These complexes are rapidly
endocytosed, and can prevent the Wnt-LRP interaction
[22, 23]. Osteoblasts produce osteoprotegerin (OPG),
which is a soluble decoy receptor for receptor activator
of nuclear factor κB ligand (RANKL) [24]. OPG inhibits
osteoclastogenesis by blocking the RANKL–RANKL re-
ceptor interaction. The activation of the canonical Wnt
pathway in osteoblasts suppresses bone resorption through
upregulation of OPG expression and downregulation of
RANKL expression [25].
Human global gene expression analyses have identified
DKK-1 as a bone mineral density (BMD)-associated gene
in postmenopausal women, and serum DKK-1 levels are
inversely associated with BMD in osteoporosis [23, 26].
DKK-1 blockade reverses both the bone-destructive pat-
tern of an inflammatory arthritis model and the bone-
forming pattern of osteoarthritis [27], whereas DKK-1
blockade promotes ankylosis of sacroiliac joints in an
experimental model [28]. Recent studies have shown the
patients with AS [29] and DISH [30] have lower serum
levels of DKK-1 than controls. This finding suggests that
the excessive ossification has some correlation with
lower serum levels of DKK-1, which, in turn, may con-
tribute to the pathogenesis of these diseases.
In this study, patients with a diagnosis of DISH, AS,
OPLL, or OYL, as assessed by radiographic and mag-
netic resonance image (MRI) studies were enrolled. Vari-
ous biomarkers of bone turnover and Wnt/β-catenin
signaling antagonists including OSC, OPG, SFRP-1,
DKK-1, and SOST were quantified. We detected the bio-
markers in serum and evaluated their association with
the spinal involvement in DISH, AS, OPLL, and OYL.
Methods
Patient’s collection
Consecutive patients with features of DISH, AS, OPLL, or
OYL at the Chang Gung Memorial Hospital were enrolled
in this study and written informed consent was obtained
from enrolled patients. Patients were diagnosed with one
of the aforementioned diseases based on the presence of
clinical features by radiographic and/or magnetic reson-
ance imaging (MRI) scans. The clinical features of anky-
losing spondylitis (AS) were: the deteriorated stiffness of
whole spine and fixed in a kyphotic deformity in the end
stage; and decreasing range of motion of the major joints,
like hips and sacroiliac joints, by the progressive ossifica-
tion of the ligament or tendinous insertion into bones.
Diffuse idiopathic skeletal hyperostosis (DISH) was char-
acterized by flawing calcification and ossification of the
anterolateral aspect of contiguous vertebral bodies (3 and
more than 3), with ossification of extra spinal sites (osteo-
phyte like). OPLL was diagnosed based on ossification of
the longitudinal ligament seen in the radiographic studies,
including lateral spine radiograms and computed tomog-
raphy (CT), extended from C1 to C7. The ossification of
yellow ligament (OYL) was defined by ossification of the
ligmentum flavum, which was located on the posterior
and lateral sides of the dural sac. Patients without a diag-
nosis of OPLL, OYL, AS, and DISH served as controls.
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Serum biomarker measurement
Fasting peripheral blood samples (10 ml) were collected
from all patients at the time of diagnosis and from con-
trols. After coagulation, serum samples were centrifuged
and stored at −80 °C until analysis. Enzyme-linked im-
munosorbent assays (ELISA) were used to measure the
levels of serum OSC (Osteocalcin Instant ELISA, Affyme-
trix eBioscience, Austria), DKK-1 (Quantikine ELISA,
R&D system, USA), sclerostin (Quantikine ELISA, R&D
system, USA), osteoprotegerin (OPG ELISA, abcam, UK),
and secreted frizzled-related protein 1 (SFRP-1 ELISA,
USCN, USA) in patient and control samples and were per-
formed according to the manufacturer’s protocols.
Statistical analysis
In this exploratory study, data are represented using the
mean ± SD. Differences in levels of biomarkers between
patients and controls were analyzed using Mann-Whitney
test. The differences between the disease groups with
respect to these serum markers were also assessed via
Mann-Whitney test. The level of significance was set at
0.05. The statistical analyses were performed using the
Excel or SPSS software package (Version 12.0, Chicago,
IL). Log10 (parameter concentration) model was used to
put all parameters into one figure in this study.
Results
Characteristics of the patients and controls
Six patients were diagnosed with AS (Male: 5, Female: 1;
age 54.0 ± 19.1 years), and 8 patients with DISH (Male:
7, Female: 1; age 60.4 ± 7.2 years). OPLL was found in 8
patients (Male: 5, Female: 3; age 58.6 ± 9.2 years), 3 patients
were diagnosed with OYL (Male: 1, Female: 2; age 62.7 ±
19.1 years), and there were 9 controls (Male: 2, Female: 7;
age 55.9 ± 15.9 years). There were no significant differences
in terms of age between the patients and the controls.
Bone turnover factors and Wnt signaling antagonists in
patients with AS and controls
Figure 1 and Table 1 summarize the circulating levels of
OSC, Dkk-1, SFRP-1, SOST, and OPG in the patients with
AS and the controls. Serum levels of OSC were higher in
the patients with AS than in the controls (**p < 0.01).
Serum levels of DKK-1 (**p < 0.01) and OPG (*p < 0.05)
were lower in the patients with AS than in the controls.
Serum levels of SFRP-1and SOST were not significantly
different between the AS patients and controls.
Bone turnover factors and Wnt signaling antagonists in
patients with DISH and controls
Figure 2 and Table 2 summarize the circulating levels of
OSC, Dkk-1, SFRP-1, SOST, and OPG in patients with
DISH and the controls. Serum levels of OSC were higher
in the patients with DISH than in the controls (**p < 0.01).
Serum levels of DKK-1 were lower in the patients with
DISH than in the controls (**p < 0.01). Serum levels of
SFRP-1 (*p < 0.05) and SOST (**p < 0.01) were higher in
the patients with DISH than in the controls. There was no
significant difference in OPG levels between the DISH
patients and controls.
Bone turnover factors and Wnt signaling antagonists in
patients with OPLL and controls
Figure 3 and Table 3 summarize the circulating levels of
OSC, Dkk-1, SFRP-1, SOST, and OPG in patients with
OPLL and controls. Serum levels of OSC (**p < 0.01) and
SOST (**p < 0.01) were higher in the patients with OPLL
than in the controls. Serum levels of DKK-1 were lower in
the patients with OPLL than in the controls (*p < 0.05).
There was no significant difference in SFRP-1 and OPG
levels between the OPLL patients and controls.
Bone turnover factors and Wnt signaling antagonists in
patients with OYL and controls
Figure 4 and Table 4 summarize the circulating levels of
OSC, DKK-1, SFRP-1, SOST, and OPG in patients with
OYL and controls. Serum levels of OSC were higher in
the patients with OYL than in the controls (*p < 0.05).
Serum levels of DKK-1 were lower in the patients with
OYL than in the controls (**p < 0.01). No significant
differences in SFRP-1, SOST and OPG levels in the OYL
patients and controls were detected.
Bone turnover factors and Wnt signaling antagonists in
patients with different diseases
Table 5 summarizes the data for bone turnover factors
and Wnt signaling antagonists in patients with different
Fig. 1 Bone turnover factors and Wnt signaling antagonists in patients
with AS and controls. Serum levels of OSC (**p < 0.01) were higher but
those of DKK-1 (**p < 0.01) and OPG (*p < 0.05) were lower in the
patients with AS than in the controls. Serum levels of SFRP-1and
SOST were not significantly different between the AS patients and
controls. (OSC, SFRP-1, and OPG: ng/ml; Dkk-1, SOST: pg/mL)
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diseases. Serum levels of OSC were higher in the OPLL
patients than those in AS patients (**p < 0.01). Serum
levels of DKK-1, SFRP-1, SOST, and OPG were not sig-
nificantly different between the disease groups (p > 0.05).
Discussion
Ankylosing spondylitis (AS) is a chronic inflammatory
disease characterized by inflammation of the spine and
can lead to bone erosion, new bone formation, and an-
kylosis of the spine. In patients with AS, after the initial
destructive changes driven by inflammation of the joint
are observed, blockade of DKK-1 relieves Wnt signaling
from DKK-1-mediated suppression and induces bone
formation, as mirrored by the growth of osteophytes
[27]. However, whether the serum levels of DKK-1 are
significantly altered in AS patients remains an unre-
solved issue. Previous studies suggested that the DKK-1
levels were lower [29], higher [31], or similar [32] in the
AS patients compared to the levels in healthy controls.
Kwon et al. [29] showed that serum DKK-1 levels were
significantly lower, but that OSC levels were significantly
higher in AS patients than those in the controls. Daoussis
et al. [31] suggested that the inhibitory effect of DKK-1 in
sera from AS patients on Wnt pathway activation was
negligible, in contrast to the clear inhibitory effect of
DKK-1 in sera from healthy donors. In the present study,
we measured DKK-1 levels in patients with AS and found
that DKK-1 levels are significantly lower in AS patients
than those in controls. In addition, the level of OSC was
significantly higher in AS patients than in controls (Fig. 1).
Consistent with the model of Diarra et al. [27] and
Kwon et al. [29], we would expect the serum DKK-1
levels in patients with AS to be suppressed but the
levels of OSC to increase during osteophyte formation.
Low serum levels of DKK-1 in AS patients suggest that
Wnt signaling is activated. Wnt activation can induce
new bone formation in arthritic joints and also allow
the growth of osteophytes.
Canonical Wnt proteins induce OPG expression, which
blocks the receptor activator of nuclear factor kappa b
ligand (RANKL)-mediated bone resorption [33]. Franck et
al. [34] and Taylan et al. [32] showed that OPG levels were
significantly lower in AS patients compared to healthy
subjects. However, some studies revealed elevated OPG
levels in AS patients compared to controls [29, 35]. Our
data showed that the OPG level was significantly lower in
AS patients than in controls (Fig. 1). We surmise that the
formation of osteophytes is directly controlled by
Wnt signaling. The proliferation and differentiation of
mesenchymal tissue that results in the formation of
osteophytes can occur independently of the RANKL–
OPG system, because inhibition of OPG does not im-
pair osteophyte formation [27].
DISH is characterized by new bone formation, calcifi-
cation, and ossification of the anterior longitudinal liga-
ment of the spine and various extra spinal ligaments [6].
Two recent studies investigated the relationship between
serum DKK-1 and DISH [30, 36]. Senolt et al. [30]
showed that the levels of total serum DKK-1 were sig-
nificantly lower in patients with DISH than in healthy
controls. Importantly, low serum levels of DKK-1 were
associated with more severe spinal involvement in DISH
[30]. However, Aeberli et al. [36] suggested that DKK-1
levels of DISH patients were not different from healthy
controls and hence development of DISH is unlikely to
Table 1 Levels of OSC, Dkk-1, SFRP-1, SOST, and OPG in the patients with AS and controls
OSC, ng/ml Dkk-1, pg/ml SFRP-1, ng/ml SOST, pg/ml OPG, ng/ml
AS (n = 6) 3.96 ± 1.03 379.8 ± 48.1 2.99 ± 0.51 368.7 ± 143.9 13.4 ± 2.3
Control (n = 9) 2.28 ± 1.37 792.5 ± 308.6 2.61 ± 1.08 261.1 ± 111.4 26.1 ± 15.3
Fig. 2 Bone turnover factors and Wnt signaling antagonists in
patients with DISH and controls. Serum levels of OSC (**p < 0.01),
SFRP-1 (*p < 0.05) and SOST (**p < 0.01) were higher in the patients
with DISH than in the controls. Serum levels of DKK-1 (**p < 0.01)
were lower in the patients with DISH than in the controls. There was
no significant difference in OPG levels between the DISH patients
and controls. (OSC, SFRP-1, OPG: ng/mL; DKK-1, SOST: pg/mL)
Table 2 Levels of OSC, Dkk-1, SFRP-1, SOST, and OPG in the













5.84 ± 2.66 311.9 ± 68.5 3.69 ± 0.86 550.6 ± 302.2 17.1 ± 9.5
Control
(n = 9)
2.28 ± 1.37 792.5 ± 308.6 2.61 ± 1.08 261.1 ± 111.4 26.1 ± 15.3
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be dependent on the Wnt signaling inhibitor DKK-1
[36]. Consistent with the model of Senolt et al. [30], we
suggest that the lower circulating DKK-1 level and
higher OSC level in patients with DISH reflect the bone
anabolic phenotype of the disease (Fig. 2).
SOST plays a critical role in bone and mineral metab-
olism. Kashii et al. [37] showed that systemic secretion
of SOST increases with higher bone mass in men with
OPLL and that serum SOST levels negatively correlate
with DKK1 levels in men with OPLL. Higher serum
SOST levels are counterbalanced by underproduction of
DKK1 [37]. In the present study, we found that the
DKK-1 levels were significantly lower in patients with
OPLL than those in controls. In addition, the levels of
SOST were significantly higher in patients than those in
controls (Fig. 3). Consistent with the model of Kashii et al.
[37], we suggest that the higher serum SOST levels are
counterbalanced by underproduction of DKK1. Fifty per-
cent of the patients with DISH also have OPLL, and OPLL
is thought to be a subtype of DISH [38]. Our study sug-
gests that changes in serum DKK-1 levels observed in pa-
tients with DISH may also represent an adaptive response
to changes in serum SOST levels (Fig. 2).
SFRP-1 inhibits Wnt signaling either by binding to
Wnts [21] or the LRP5/6 complex [39] to prevent the
Wnt - LRP5/6 interaction. Consistent with the model of
Taylan et al. [40], our data showed that the level of
SFRP-1 was similar between the AS patients and con-
trols (Fig. 1). Because SOST and SFRP-1 both act as
extracellular antagonists of the Wnt/β-catenin signaling
pathway, we suggest that SOST and SFRP-1 play similar
roles in patients with DISH. Our data showed the higher
levels of SFRP-1 and SOST and lower levels of DKK-1 in
patients with DISH (Fig. 2) than those in controls. Simi-
lar to SOST, elevated serum SFRP-1 levels may be coun-
terbalanced by underproduction of DKK-1.
Sugimori et al. [40] reported that the concentrations of
OSC were significantly higher in patients with OPLL
than those in controls. Thus, the serum concentration of
OSC may reflect the activity of general ectopic bone for-
mation in patients with OPLL [40]. However, Ishihara et
al. [41] and Matsui et al. [42] reported that serum OSC
levels were similar in persons with OPLL and in control
groups. In the present study, we found that the OSC
levels were significantly higher in patients than those in
controls (Fig. 3). Consistent with the model of Sugimori
Fig. 3 Bone turnover factors and Wnt signaling antagonists in patients
with OPLL and controls. Serum levels of OSC (**p < 0.01) and SOST
(**p < 0.01) were higher but those of DKK-1 (*p < 0.05) were lower in
the patients with OPLL than in the controls. There was no significant
difference in SFRP-1 and OPG levels between the OPLL patients and
controls. (OSC, SFRP-1, OPG: ng/mL; Dkk-1, SOST: pg/mL)
Table 3 Levels of OSC, Dkk-1, SFRP-1, SOST, and OPG in the













7.95 ± 3.91 395.8 ± 260.1 3.82 ± 1.17 499.4 ± 104.1 17.2 ± 8.2
Control
(n = 9)
2.28 ± 1.37 792.5 ± 308.6 2.61 ± 1.08 261.1 ± 111.4 26.1 ± 15.3
Fig. 4 Bone turnover factors and Wnt signaling antagonists in patients
with OYL and controls. Serum levels of OSC (*p < 0.05) were higher but
those of DKK-1 (**p < 0.01) were lower in the patients with OYL than in
the controls. No significant differences in SFRP-1, SOST and OPG levels
in the OYL patients and controls were detected. (OSC, SFRP-1, OPG:
ng/mL; Dkk-1, SOST: pg/mL)
Table 4 Levels of OSC, Dkk-1, SFRP-1, SOST, and OPG in the













5.62 ± 1.78 316.1 ± 112.1 3.61 ± 0.49 368.9 ± 91.4 18.7 ± 3.79
Control
(n = 9)
2.28 ± 1.37 792.5 ± 308.6 2.61 ± 1.08 261.1 ± 111.4 26.1 ± 15.3
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et al. [40], we found that the serum DKK-1 levels in pa-
tients with OPLL are suppressed, whereas the levels of
OSC are increased, during osteophyte formation.
OYL is characterized by progressive ectopic bone for-
mation in the spinal ligaments. Decreased DNA methy-
lation in the promoter region of the Wnt5a and glial cell
line-derived neurotrophic factor (GDNF) genes may pro-
mote the osteogenic ability of mesenchymal stem cells
(MSCs) from patients with OYL [43]. However, the levels
of bone turnover biomarkers, including OSC, OPG, SFRP-
1, DKK-1, and SOST in serum have never been reported.
Our data show that the serum DKK-1 levels in patients
with OYL are suppressed but the levels of OSC are in-
creased during osteophyte formation (Fig. 4).
Many previous studies showed that persons with
OPLL, who often also have DISH, have a significantly
higher BMD than control-groups [44, 45]. In this study,
we mainly focused on the patients who were diagnosed
with one type of the diseases associated with aberrant
bone turnover. Although the serum levels of OSC, DKK-
1, SFRP-1, SOST, and OPG were not significantly differ-
ent between patients with one of these diseases (Table 5),
we found that OSC levels were higher in OPLL (7.95 ±
3.91 ng/mL) than in AS (3.96 ± 1.03 ng/mL) patients
(**p < 0.01). OPLL was found to be associated with more
severe axial disease [15]. We hypothesize that the higher
levels of OSC may be associated with the pathogenesis
of OPLL progression.
We note that our study has several limitations. Our
experiments were limited to a small number of samples
in each group, it could be argued that the differences we
observed were even more significant given the small size
of the experimental groups. Because of the small number
of patients, we could not find the correlations between
serum parameters and clinical parameters of disease
severity and progression in this study. We intend to ad-
dress the relationship between disease severity and pro-
gression and serum biomarkers in a study with a larger
set of patients in the future. In addition, OPLL has been
associated with several diseases, including DISH ad AS.
The serum markers in patients with more one of these
bone turnover-related disease warrants further investiga-
tion. Recently, studies have demonstrated that dysfunc-
tional MSCs contributes to many diseases. Considering
that MSCs are a major source of osteoblasts, pathologic
osteogenesis of MSCs in patients with AS, DISH, OPLL,
and OYL are still controversial subjects.
Conclusions
In this exploratory study, serum OSC levels were higher
but DKK-1 levels were lower in AS, DISH, OPLL, and
OYL patients than those in controls. Our results suggests
that blood OSC and DKK-1 levels may serve as biomarkers
for AS, DISH, OPLL, and OYL diagnosis. In addition,
DISH and OPLL, DISH and OYL, OPLL and OYL, and AS
and OYL have been noted to coexist in the same patients.
Because of the disease overlapping, the present observa-
tions provide insights on the OSC and DKK-1 related
mechanisms underlying the development of AS, DISH,
OPLL, and OYL; and they ultimately may lead to potential
drug therapies for management of these diseases. Future
studies with larger subject cohorts are warranted to con-
firm the findings of this exploratory study.
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